首页> 外文期刊>The Internet Journal of Gastroenterology >Evaluation Of Safety And Efficacy Of Pantoprazole And Domperidone Combination In Patients With Gastroesophageal Reflux Disease
【24h】

Evaluation Of Safety And Efficacy Of Pantoprazole And Domperidone Combination In Patients With Gastroesophageal Reflux Disease

机译:潘托拉唑与多潘立酮联合治疗胃食管反流病的安全性和有效性评价

获取原文
           

摘要

Background: Gastro-esophageal reflux disease (GERD) and non ulcer dyspepsia (NUD) are overlapping disorders with common symptomatology. The combination is synergistic by decreasing acid production as well as increasing lower esophageal tone & esophageal clearance thus producing a better therapeutic response. Objective: To evaluate the safety and efficacy of the combination Methods: In patients satisfying the inclusion and exclusion criteria for GERD (Group A, n=105) and Non Erosive GERD (Group B, n=19) baseline symptomatology, endoscopy & laboratory investigations were done followed by test medication once daily for 28 days & monitored for symptom improvement at week 1, 2, & 4 and endoscopy and laboratory investigations at week 4. Results: Of Group A patients having erosive GERD 68/94 (72.34%) were completely cured, 19/94 (20.21%) partially cured, 7/94 (7.44%) not cured. All patients having Non-Erosive GERD had significant improvement in symptoms at 4 week from baseline. Conclusion: Combination of pantoprazole and domperidone is a effective & safe combination with high symptom improvement rates. Introduction GERD is one of the commonest esophageal disorder, with overlapping symptomatology with NUD. Erosive GERD is differentiated from functional dyspepsia by positive endoscopic findings but there is a considerable overlap between functional dyspepsia & non-erosive reflux disease. There is a controversy with regard to whether symptoms of heartburn & acid regurgitation should be considered as a part of NUD or not. Rome II definition considers them to be indicative of GERD whereas others believe them to be a part of dyspepsia1. We believe these to be a spectrum of disease with some patients having erosive esophagitis and others not but most having common symptoms. The basic mechanisms underline the spectrum are –increased acid production, decreased tone of lower esophageal sphincter (LES) & disturbances in gut motility. In fact, National Disease and Therapeutic Index data (U.S.A.) has shown that physicians are writing more than 20% of omeprazole and lansoprazole prescriptions in combination with other medications, including H2RAs and prokinetic agents, or for twice-daily administration, in an effort to combat difficult cases of acid reflux.2 With respect to reports with combination of anti-secretory with prokinetics in GERD & NUD from India, study by Madan et al. has shown that combination of pantoprazole and mosapride has better symptomatic relief than pantoprazole alone in cases of GERD whereas healing rates are similar.3 Another such study comparing ranitidine and domperidone with ranitidine alone has found better symptom improvement with the combination.4 We designed the study with an objective to evaluate the therapeutic efficacy and safety of combination of pantoprazole with domperidone in management of GERD. Materials And Methods The study was an open-label, non-comparative, non-randomized study carried out in 3 large medical college hospitals and one specialist digestive disease hospital in India during September 2003 to march 2004. Informed consent was obtained from the patients & the study was in accordance with the clinical principles laid down in declaration of Helsinki. A minimum of 100 subjects were to be enrolled at 4 centers to account for dropouts a total of 124 patients were recruited for the study. Inclusion CriteriaPatients of either sex 18 yrs or more willing to give informed consentPatients endoscopically classified according to modified Hetzel-Dent grade 1-3 esophagitis5.Grade 0- no mucosal abnormality; Grade 1- no macroscopic erosions but erythema, hyperemia/mucosal friability; Grade 2- superficial erosion involving 1. (None) no symptoms: 2. (mild) symptoms can be easily ignored: 3. (mod) awareness of symptoms but easily tolerated: 4. (severe) symptoms sufficient enough to cause interference with normal activities: 5. (incapacitating) inability to perform daily activities and/or require days off work. The q
机译:背景:胃食管反流病(GERD)和非溃疡性消化不良(NUD)是常见症状的重叠疾病。该组合通过减少酸产生以及增加较低的食道张力和食道清除率而具有协同作用,从而产生更好的治疗反应。目的:评价联合用药的安全性和有效性。方法:对于符合GERD(A组,n = 105)和非侵蚀性GERD(B组,n = 19)基线症状,内镜和实验室检查的患者每天接受一次为期28天的测试药物治疗,并在第1、2和4周进行症状改善监测,并在第4周进行内窥镜检查和实验室检查。结果:A组患有侵蚀性GERD 68/94(72.34%)的患者为完全固化,部分固化的19/94(20.21%),未固化的7/94(7.44%)。从基线开始第4周,所有患有非侵蚀性GERD的患者的症状都有明显改善。结论:pan托拉唑与多潘立酮联合使用是一种安全有效的方法,具有较高的症状改善率。简介GERD是最常见的食道疾病之一,症状与NUD重叠。内镜检查阳性可将侵蚀性GERD与功能性消化不良区分开,但功能性消化不良和非侵蚀性反流病之间存在相当大的重叠。关于是否应将烧心和胃酸反流的症状视为NUD的一部分存在争议。罗马二世的定义认为它们是GERD的指标,而其他人则认为它们是消化不良的一部分。我们认为,这是一种疾病,有些患者患有糜烂性食管炎,而其他一些患者则没有,但大多数都有常见症状。频谱的基本机制是–产酸增加,下食管括约肌(LES)音调降低和肠蠕动紊乱。实际上,美国国家疾病与治疗指数(National Disease and Therapeutic Index)数据(美国)已表明,医生正在与其他药物(包括H2RA和促运动药)或每天两次联合服用奥美拉唑和兰索拉唑处方的20%以上,以期Madan等人的研究报道了印度GERD和NUD中结合抗分泌药和促运动药的报道。2已表明,在GERD病例中,top托拉唑和莫沙必利的组合比单独使用top托拉唑具有更好的症状缓解,而治愈率相似。3另一项比较雷尼替丁和多潘立酮与雷尼替丁单独使用的研究发现,联合使用可改善症状。4我们设计了该研究目的是评估pan托拉唑与多潘立酮联合治疗GERD的疗效和安全性。资料和方法该研究是2003年9月至2004年3月在印度的3家大型医学院医院和1家消化病专科医院进行的开放标签,非比较,非随机的研究。该研究符合赫尔辛基宣言中规定的临床原则。至少有100名受试者将在4个中心招募,以解决辍学问题,总共招募了124名患者进行研究。纳入标准年龄在18岁或18岁以上且愿意征得知情同意的患者根据改良的Hetzel-Dent 1-3级食管炎进行内镜分类的患者5.等级0-无粘膜异常; 1级-没有肉眼可见的糜烂,但有红斑,充血/粘膜脆性; 2级浅表侵蚀,涉及1.(无)无症状:2.(轻度)症状可轻易忽略:3.(mod)对症状的认识但易于耐受:4.(严重)足以引起正常干扰的症状活动:5.(使人无法)不能进行日常活动和/或需要休息几天。 q

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号